1. Home
  2. TYL vs UTHR Comparison

TYL vs UTHR Comparison

Compare TYL & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tyler Technologies Inc.

TYL

Tyler Technologies Inc.

HOLD

Current Price

$350.74

Market Cap

15.0B

Sector

Technology

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$527.30

Market Cap

23.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TYL
UTHR
Founded
1966
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0B
23.9B
IPO Year
1996
1999

Fundamental Metrics

Financial Performance
Metric
TYL
UTHR
Price
$350.74
$527.30
Analyst Decision
Buy
Buy
Analyst Count
11
14
Target Price
$478.91
$531.79
AVG Volume (30 Days)
559.9K
485.2K
Earning Date
04-22-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
19.01
13.07
EPS
7.20
27.86
Revenue
$493,101,000.00
$1,483,300,000.00
Revenue This Year
$9.63
$7.77
Revenue Next Year
$9.66
$11.11
P/E Ratio
$47.79
$19.04
Revenue Growth
18.35
2.38
52 Week Low
$283.72
$266.98
52 Week High
$621.34
$548.12

Technical Indicators

Market Signals
Indicator
TYL
UTHR
Relative Strength Index (RSI) 46.65 57.52
Support Level $320.23 $464.92
Resistance Level $373.88 $542.66
Average True Range (ATR) 11.40 14.24
MACD 1.32 1.62
Stochastic Oscillator 20.40 74.46

Price Performance

Historical Comparison
TYL
UTHR

About TYL Tyler Technologies Inc.

Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: